Myia Labs Secures $6.75M Seed Funding to Enhance Patient Vital Monitoring via AI-Powered Integration with Apple Watches and Fitbits

VCBeat (WeChat Official Account: vcbeat) learned from foreign media reports that Myia Labs, a platform company applying AI health monitoring technology to consumer-facing wearable devices, raised $6.75 million in seed funding on November 30. The round was led by BootstrapLabs and Zetta Venture Partners, with participation from the American College of Cardiology (ACC) and Boston Consulting Group.

Myia leverages machine learning to identify significant changes in patients’ vital signs, providing monitoring capabilities tailored for individuals with chronic conditions or post-operative care needs on Apple Watches, Fitbits, and other wearable devices. Specifically, the company’s product employs machine learning algorithms to monitor the wearer’s heart rate, heart rate variability, respiratory rate, blood pressure, and sleep patterns. If any abnormalities are detected, patients receive immediate alerts from the company.

Image source: Myia Labs official website

“We have accumulated years of real-world health data traffic, but to transform this data into trustworthy, actionable clinical insights and deliver preventive virtual care in novel ways, we need more advanced machine learning and artificial intelligence technologies,” said Simon MacGibbon, CEO of Myia, in a statement. “Many biometric markers for identifying patient health status have been established in academic settings but remain inaccessible and untranslatable for practical use. We are excited to collaborate with leaders in the medical community to bring real-world insights to clinics.”

Consumer interest in wearable devices is growing, leading to their increasing adoption in healthcare and wellness. Although these devices are primarily used for consumer-side health tracking, powered by software developed by Myia and supported by physician organizations such as the American College of Cardiology (ACC), wearables will gain the capability to provide proactive care to users.

Dr. John Rumsfeld, Chief Innovation Officer of the American College of Cardiology (ACC), stated in a press release: “Our collaboration with Myia is developing tools for our clinical teams to monitor and improve patient health outcomes. Myia’s emphasis on ‘co-creation’ between patients and physicians aligns perfectly with the ACC’s definition of healthcare innovation—patient-centered care that leverages advanced technologies to deliver high-quality services.”

Recent studies have particularly highlighted the value of wearable devices in monitoring chronic disease care. Over the past year, companies such as Fitbit and Apple have taken significant steps to enhance the healthcare capabilities of their wearable devices. In addition to consumer-oriented wearable device development, other startups have developed wearable patient monitors specifically for medical use and have secured investment funding.

Nicolai Wadstrom, Founder and CEO of investor BootstrapLabs, stated: “Myia is truly exciting; they empower patients to take charge of their own health. Moreover, Myia has the opportunity to eventually expand its business into cardiovascular-related health issues, thereby alleviating some of the most severe diseases facing our society.”

Myia Labs is an early-stage intelligent health monitoring platform dedicated to remote health monitoring for patients with chronic diseases. Founded in 2017 and headquartered in California, USA, Myia primarily leverages wearable devices such as the Apple Watch, Fitbit, and Motiv Ring to monitor the health status of chronic disease patients, aiming to predict relapses before they occur.

BootstrapLabs is a venture capital firm based in San Francisco, USA. The company’s investment areas include transportation, logistics, fintech, security, and the Internet of Things (IoT).